Theriva Biologics amends ATM sales agreement with A.G.P., terminates B. Riley

Theriva Biologics, Inc.

Entered Amendment No. 2 to At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners on May 2, 2024.
Amendment updates registration statement to new Form S-3 filed May 2, 2024 for future at-the-market offerings.
B. Riley Securities, Inc. agreed to termination as party to the Sales Agreement effective May 1, 2024.
Other terms of the original agreement remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.